Eribulin

• Description:

  Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

• Product Name Alternative:

  B1939; E7389; ER-086526

• UNSPSC:

  12352203

• Hazard Statement:

  H301+H311+H331, H341, H351, H361

• Target:

  ADC Payload; Apoptosis; Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/eribulin.html

• Purity:

  99.92

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)

• Smiles:

  C=C1C[C@@](CC[C@@]2(C[C@@]3([H])O4)O[C@]([C@](O[C@](C5)([H])CC6)([H])[C@@]6([H])O7)([H])[C@@]4([H])[C@]7([H])[C@@]3([H])O2)([H])O[C@@]1([H])CC[C@](C[C@@H](C)C8=C)([H])O[C@]8([H])C[C@@](O[C@H](C[C@H](O)CN)[C@@H]9OC)([H])[C@]9([H])CC5=O

• Molecular Formula:

  C40H59NO11

• Molecular Weight:

  729.90

• Precautions:

  H301+H311+H331, H341, H351, H361

• References & Citations:

  [1]Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7 (7) : p. 2003-11.|[2]Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49 (6) : p. 1331-7.|[3]Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71 (2) : p. 496-505.|[4]Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10 (2) : 161-174.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category:

  ADC Related

• Clinical Information:

  Launched

• Citation 01:

  Dev Cell. 2025 Mar 25:S1534-5807 (25) 00151-0.|iScience. 2022 Sep 6;25 (10) :105081.|J Control Release. 2025 Oct 14;388 (Pt 1) :114325.|NPJ Breast Cancer. 2025 Feb 17;11 (1) :17.|Res Sq. 2024 Sep 17.|Cell Rep Med. 2025 Apr 2:102053.|mBio. 2025 Aug 15:e0048425.|Molecules. 2025 Feb 14;30 (4) :895.

• CAS Number:

  [253128-41-5]